NexMed Announces New Patent Issued For Proprietary Medicament Dispenser

Apr 25, 2001, 01:00 ET from NexMed, Inc.

    ROBBINSVILLE, N.J., April 25 /PRNewswire Interactive News Release/ --
 NexMed, Inc. (Nasdaq:   NEXM), a developer of innovative treatments for sexual
 dysfunction, announced today that the U.S. Patent & Trademark Office is
 issuing U.S. Patent Number 6,224,573 for the Company's application on the
 medicament dispenser.  The patent covers the dispenser used in the specially
 designed packaging of the Alprox-TD(R) and Femprox(TM) creams for erectile
 dysfunction ("ED") and female sexual arousal disorder ("FSAD"), respectively.
     NexMed developed the medicament dispenser to facilitate patient compliance
 for treatments involving small amounts of topical medications such as creams,
 ointments, or gels.  The Alprox-TD(R) and Femprox(TM) products are pre-filled
 and packaged in the new unit-dose dispenser which will be an added convenience
 to the patient.  The new dispenser is designed to provide accurate and
 controlled dosing of a small amount of medication directly to the targeted
 area of treatment thereby reducing dosing errors and waste.
     Dr. James L. Yeager, Vice-President of R&D, commented, "Our 'target dose
 dispenser' is an innovative and important new concept in the dosing of topical
 medications and has been incorporated in the total product design of our
 Alprox-TD(R) and Femprox(TM) products."  Dr. Yeager added, "We anticipate that
 patients using either the Alprox-TD(R) or Femprox(TM) products will benefit
 from the use of our small pre-filled dispenser that is discrete, portable,
 disposable, quickly and easily opened, and designed to deliver an accurate
 dose directly to the site of application."
     NexMed has completed two Phase II studies for the Alprox-TD(R) product and
 is entering into pivotal Phase III studies in the U.S., pending FDA
 concurrence.  For Femprox(TM), the Company is in the process of initiating a
 Phase II study, which will include 100 patients at 11 sites in the U.S.
 
     About NexMed, Inc.
     NexMed, Inc., is an emerging pharmaceutical and medical technology
 company, with a product development pipeline of innovative topical drug
 treatments based on the NexACT(R) acute transdermal delivery technology.  Its
 two lead NexACT(R) products under development are the Alprox-TD(R) and
 Femprox(TM) creams for ED and FSAD, respectively.   In addition, NexMed is
 developing Viratrol(R), a hand-held treatment device for herpes simplex.
 
     Statements under the Private Securities Litigation Reform Act: with the
 exception of the historical information contained in this release, the matters
 described herein contain forward-looking statements that involve risk and
 uncertainties that may individually or mutually impact the matters herein
 described, including but not limited to product development and acceptance,
 manufacturing, competition, regulatory and/or other factors, which are outside
 the control of the Company.
 
                     MAKE YOUR OPINION COUNT -- Click Here
                http://tbutton.prnewswire.com/prn/11690X00228264
 
 

SOURCE NexMed, Inc.
    ROBBINSVILLE, N.J., April 25 /PRNewswire Interactive News Release/ --
 NexMed, Inc. (Nasdaq:   NEXM), a developer of innovative treatments for sexual
 dysfunction, announced today that the U.S. Patent & Trademark Office is
 issuing U.S. Patent Number 6,224,573 for the Company's application on the
 medicament dispenser.  The patent covers the dispenser used in the specially
 designed packaging of the Alprox-TD(R) and Femprox(TM) creams for erectile
 dysfunction ("ED") and female sexual arousal disorder ("FSAD"), respectively.
     NexMed developed the medicament dispenser to facilitate patient compliance
 for treatments involving small amounts of topical medications such as creams,
 ointments, or gels.  The Alprox-TD(R) and Femprox(TM) products are pre-filled
 and packaged in the new unit-dose dispenser which will be an added convenience
 to the patient.  The new dispenser is designed to provide accurate and
 controlled dosing of a small amount of medication directly to the targeted
 area of treatment thereby reducing dosing errors and waste.
     Dr. James L. Yeager, Vice-President of R&D, commented, "Our 'target dose
 dispenser' is an innovative and important new concept in the dosing of topical
 medications and has been incorporated in the total product design of our
 Alprox-TD(R) and Femprox(TM) products."  Dr. Yeager added, "We anticipate that
 patients using either the Alprox-TD(R) or Femprox(TM) products will benefit
 from the use of our small pre-filled dispenser that is discrete, portable,
 disposable, quickly and easily opened, and designed to deliver an accurate
 dose directly to the site of application."
     NexMed has completed two Phase II studies for the Alprox-TD(R) product and
 is entering into pivotal Phase III studies in the U.S., pending FDA
 concurrence.  For Femprox(TM), the Company is in the process of initiating a
 Phase II study, which will include 100 patients at 11 sites in the U.S.
 
     About NexMed, Inc.
     NexMed, Inc., is an emerging pharmaceutical and medical technology
 company, with a product development pipeline of innovative topical drug
 treatments based on the NexACT(R) acute transdermal delivery technology.  Its
 two lead NexACT(R) products under development are the Alprox-TD(R) and
 Femprox(TM) creams for ED and FSAD, respectively.   In addition, NexMed is
 developing Viratrol(R), a hand-held treatment device for herpes simplex.
 
     Statements under the Private Securities Litigation Reform Act: with the
 exception of the historical information contained in this release, the matters
 described herein contain forward-looking statements that involve risk and
 uncertainties that may individually or mutually impact the matters herein
 described, including but not limited to product development and acceptance,
 manufacturing, competition, regulatory and/or other factors, which are outside
 the control of the Company.
 
                     MAKE YOUR OPINION COUNT -- Click Here
                http://tbutton.prnewswire.com/prn/11690X00228264
 
 SOURCE  NexMed, Inc.